CureApp HT CKD Trial

JRCT ID: jRCTs052220164

Registered date:07/02/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Chronic Kidney Disease
• Date of first enrollment: 13/02/2023
• Target sample size: 100
• Study type: Interventional

Intervention(s)

1. Intervention Group
Use of CureApp HT for 12 weeks + Usual lifestyle modification
2. Control Group
Usual lifestyle modification

Outcome(s)

• Primary Outcome: Change in 24-hour urinary sodium excretion

Secondary Outcome

1) Office blood pressure
2) Pulse wave velocity
3) Urinary protein creatinine ratio
4) Urinary potassium creatinine ratio
5) Urinary sodium potassium ratio
6) estimated Glomerular Filtration Rate
7) Brain natriuretic peptide
8) Body weight
9) Dose of antihypertensive drugs
10) Adverse events

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1) Age 18 years or older
2) CKD stage1 to 5 patients referred to the outpatient department of nephrology at Osaka University Hospital
3) History of hypertension (the systolic blood pressure is >=140 mmHg and/or the diastolic blood pressure is >=90 mmHg) and/or prescription of antihypertensive drugs
4) Urinary sodium excretion >=100 mmol/day
5) Written informed consent

Exclude criteria

1) Use of other healthcare applications
2) Inability to use the application (by the patient or family members)

Related Information

• Primary Sponsor: Sakaguchi Yusuke